Aktis Oncology (NASDAQ:AKTS) Stock Price Down 10% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s share price was down 10% on Monday . The company traded as low as $30.12 and last traded at $28.5720. Approximately 53,438 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 334,355 shares. The stock had previously closed at $31.76.

Wall Street Analysts Forecast Growth

AKTS has been the topic of several recent research reports. Raymond James Financial started coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price on the stock. William Blair initiated coverage on Aktis Oncology in a research report on Wednesday, April 29th. They issued an “outperform” rating for the company. HC Wainwright boosted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Performance

The stock has a market capitalization of $1.47 billion and a price-to-earnings ratio of -72.58. The stock has a fifty day moving average of $22.20.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million for the quarter. Analysts expect that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.